Published in Br J Cancer on June 01, 1992
Advanced breast cancer: use of resources and cost implications. Br J Cancer (1993) 1.48
Regional trends in breast cancer incidence and mortality in Denmark prior to mammographic screening. Br J Cancer (1994) 1.05
A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics (1996) 1.02
Quantitative estimates of the impact of sensitivity and specificity in mammographic screening in Germany. J Epidemiol Community Health (1997) 0.91
Cost-effectiveness of early detection of breast cancer in Catalonia (Spain). BMC Cancer (2011) 0.85
Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Br J Cancer (1995) 0.84
Changes in use of breast-conserving therapy in years 1978-2000. Br J Cancer (1994) 0.83
Effect of radiotherapy on the interpretation of routine follow-up mammography after conservative breast surgery: a randomized study. Br J Cancer (1998) 0.80
Health services research in oncology. Br J Cancer (1993) 0.75
Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. BMJ (1988) 9.71
Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet (1990) 6.17
Breast screening: time for a rethink? BMJ (1989) 5.52
Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer (1990) 5.34
The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health (1989) 5.20
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
Psychiatric morbidity associated with screening for breast cancer. Br J Cancer (1989) 2.53
Psychosocial status in chronic illness. A comparative analysis of six diagnostic groups. N Engl J Med (1984) 2.24
Breast cancer screening: the current position. BMJ (1991) 2.17
Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer (1991) 1.97
A model for breast cancer screening. Cancer (1990) 1.96
Estimating the treatment costs of breast and lung cancer. Med Care (1991) 1.80
The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer (1991) 1.57
A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer (1991) 1.32
Screening for recurrent breast cancer--its effectiveness and prognostic value. J Clin Oncol (1987) 1.26
Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires. Br J Cancer (1991) 1.21
Does more intense palliative treatment improve overall survival in metastatic breast cancer patients? Cancer (1986) 1.16
Psychosocial consequences of cancer chemotherapy for elderly patients. Health Serv Res (1986) 1.11
Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncológico Cooperativo del Sur. Am J Clin Oncol (1990) 1.05
Morbidity after breast biopsy for benign disease in a screened population. Lancet (1992) 0.92
Breast cancer screening: its impact on clinical medicine. Br J Cancer (1990) 0.89
Treatment of the terminal stages of breast cancer. BMJ (1989) 0.85
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
Doctor-patient communication: a review of the literature. Soc Sci Med (1995) 10.48
The health care costs of smoking. N Engl J Med (1997) 8.59
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
The friction cost method for measuring indirect costs of disease. J Health Econ (1995) 5.55
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer (1999) 5.47
Life-terminating acts without explicit request of patient. Lancet (1993) 5.39
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst (1995) 4.23
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 4.13
Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst (2000) 3.92
Evaluation of the notification procedure for physician-assisted death in the Netherlands. N Engl J Med (1996) 3.80
Medical end-of-life decisions made for neonates and infants in the Netherlands. Lancet (1997) 3.70
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet (1997) 3.68
Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet (1995) 3.61
Double-blind placebo-controlled study of the hyperventilation provocation test and the validity of the hyperventilation syndrome. Lancet (1996) 3.42
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet (1998) 3.28
Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health (1994) 3.10
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet (2000) 2.84
Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. BMJ (1998) 2.80
Clinical problems with the performance of euthanasia and physician-assisted suicide in The Netherlands. N Engl J Med (2000) 2.64
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
[Joint decisions, how? Physician-patient communication about palliative chemotherapy]. Ned Tijdschr Geneeskd (1997) 2.34
Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol (2001) 2.33
The emotional impact on physicians of hastening the death of a patient. Med J Aust (2001) 2.29
Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol (2001) 2.25
Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry (1996) 2.17
Post-1950 mortality trends and medical care: gains in life expectancy due to declines in mortality from conditions amenable to medical intervention in The Netherlands. Soc Sci Med (1988) 2.11
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
[Arguments for offering triple test serum screening for Down's syndrome to all pregnant women]. Ned Tijdschr Geneeskd (2002) 2.03
Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy. Br J Cancer (1996) 2.01
Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol (1999) 1.99
The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res (1999) 1.98
Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer (1991) 1.97
A model for breast cancer screening. Cancer (1990) 1.96
Nationwide breast cancer screening programme fully implemented in The Netherlands. Breast (2001) 1.88
Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res (2001) 1.78
Somatostatin receptors in human endocrine tumors. Cancer Res (1987) 1.77
The quality of life of cancer patients: a review of the literature. Soc Sci Med (1985) 1.76
The reproductive lifespan of Onchocerca volvulus in West African savanna. Acta Trop (1991) 1.76
[Fourth evaluation of the law on the review of termination of life on request and assisted suicide (Euthanasia Act)]. Ned Tijdschr Geneeskd (2005) 1.71
ONCHOSIM: a model and computer simulation program for the transmission and control of onchocerciasis. Comput Methods Programs Biomed (1990) 1.70
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review. J Clin Oncol (1991) 1.67
The role of parents in end-of-life decisions in neonatology: physicians' views and practices. Pediatrics (1998) 1.65
Comparing methodologies for the cost estimation of hospital services. Eur J Health Econ (2008) 1.64
Regional differences in mortality from conditions amenable to medical intervention in The Netherlands: a comparison of four time periods. J Epidemiol Community Health (1988) 1.64
Using potentially life-shortening drugs in neonates and infants. Crit Care Med (2000) 1.63
Variations in 'avoidable' mortality: a reflection of variations in incidence? Int J Epidemiol (1999) 1.60
Physician-assisted death in psychiatric practice in the Netherlands. N Engl J Med (1997) 1.60
c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res (1992) 1.59
[No conspicuous changes in the practice of medical end-of-life decision-making for neonates and infants in the Netherlands in 2001 as compared to 1995]. Ned Tijdschr Geneeskd (2005) 1.59
The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer (1991) 1.57
Assessment of physician-assisted death by members of the public prosecution in The Netherlands. J Med Ethics (1999) 1.56
Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst (2000) 1.54
[Trends in the agents used for euthanasia and the relationship with the number of notifications]. Ned Tijdschr Geneeskd (2006) 1.54
Towards a new approach for estimating indirect costs of disease. Soc Sci Med (1992) 1.54
The effect of radical and conserving surgery on the quality of life of early breast cancer patients. Eur J Surg Oncol (1986) 1.53
Consultants in cases of intended euthanasia or assisted suicide in The Netherlands. Med J Aust (1999) 1.52
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol (2000) 1.51
Large scale ivermectin distribution and its epidemiological consequences. Acta Leiden (1990) 1.51
Doctor-patient communication and cancer patients' quality of life and satisfaction. Patient Educ Couns (2000) 1.50
Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the Health Insurance Plan of Greater New York study. J Natl Cancer Inst (1986) 1.50
Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res (1989) 1.48
Deciding about continuous deep sedation: physicians' perspectives: a focus group study. Palliat Med (2009) 1.48
Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores. Med Decis Making (1994) 1.46
Fatigue in cancer patients. Br J Cancer (1993) 1.45
Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears. Am J Clin Pathol (2001) 1.45
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res (1992) 1.44
[Good results in periodic screening in women with increased risk of breast cancer; retrospective study]. Ned Tijdschr Geneeskd (1995) 1.44
Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res (1990) 1.43
Inaccuracies in estimates of life expectancies of patients with bronchial cancer in clinical decision making. Med Decis Making (1993) 1.43
ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet (2000) 1.42
The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem (1995) 1.42
Health of migrants and migrant health policy, The Netherlands as an example. Soc Sci Med (1995) 1.40
[Did hypertension diminish in The Netherlands between 1974 and 1993?]. Ned Tijdschr Geneeskd (1996) 1.40
Follow-up of colorectal cancer patients: quality of life and attitudes towards follow-up. Br J Cancer (1997) 1.40
A measure of survival time for long-term follow-up studies of the elderly. J Clin Epidemiol (1989) 1.39
The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed (1985) 1.39
[Chemotherapy in metastasized breast carcinoma]. Ned Tijdschr Geneeskd (1998) 1.38
[Reasons why patients do or do not participate in clinical trials; a systemic review of the literature]. Ned Tijdschr Geneeskd (2004) 1.38
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol (1994) 1.36
Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst (1998) 1.36
How cost-effective is breast cancer screening in different EC countries? Eur J Cancer (1993) 1.35
Economic aspects of cervical cancer screening. Soc Sci Med (1990) 1.34
Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol (2001) 1.34
Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer (2001) 1.34
The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer (1996) 1.34
Nation-wide breast cancer screening in The Netherlands: support for breast-cancer mortality reduction. National Evaluation Team for Breast Cancer Screening (NETB). Int J Cancer (1995) 1.34
Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res (1989) 1.32
Nation-wide breast cancer screening in The Netherlands: results of initial and subsequent screening 1990-1995. National Evaluation Team for Breast Cancer Screening. Int J Cancer (1998) 1.31